Solid-state characterization and pharmaceutical compatibility between citalopram and excipients using thermal and non-thermal techniques
Differential scanning calorimetry (DSC) has been used in combination with powder X-ray diffraction (PXRD) and solid-state nuclear magnetic resonance (SSNMR) for evaluation of drug–excipient interaction. This study aimed to evaluate the antidepressive citalopram hydrobromide and the most usual excipient commonly used for the evaluation of their compatibility in binary mixtures. The TG/DTG curves reveal that citalopram is thermally stable up to 230 °C, presenting a sharp endothermic peak at 183 °C (T onset = 185 °C) that corresponds to its melting point. Only for citalopram–lactose binary mixture was observed dislocation of the melting event in the DSC curves; however, this change has not indicated to be an interaction between the components in this case, but an overlap of events of lactose and citalopram. PXRD pattern suggests that no interaction is present between individual components that still showing the same crystalline structure for citalopram. The SSNMR spectrum assignment was done based on computational prediction of chemical shifts comparing it with its original spectrum. The chemical shifts confirmed the expected structure. Therefore, since changes in chemical shift are smaller than 1 ppm, no evidence of chemical interaction between the components of each binary mixture was confirmed.
KeywordsCitalopram Compatibility studies Thermal analysis PXRD SSNMR
The authors are grateful to CNPq, CAPES, and FAPEMIG for the financial support.
- 1.Oruch R, Hodneland E, Pryme IE, Holmsen H. In thrombin stimulated human platelets citalopram, promethazine, risperidone, and ziprasidone, but not diazepam, may exert their pharmacological effects also through intercalation in membrane phospholipids in a receptor-independent manner. J Chem Biol. 2009;2:89–103.CrossRefGoogle Scholar
- 5.ICH Stability testing of new drug substances and products. In: Proceedings of the international conference on Harmonization. Geneva: IFPMA; 2003.Google Scholar
- 11.Holzgrabe U, Diehl B, Wawer I. NMR spectroscopy in pharmaceutical analysis. Amsterdam: Elsevier; 2008.Google Scholar
- 16.Yasmeen BR, Firoz S, Mouli YC, Vikram A, Mahitha B, Aruna U. Preparation and evaluation of oral fast dissolving films of citalopram hydrobromide. Int J Biopharma. 2012;3:103–6.Google Scholar
- 17.The (USP) Convention. United States Pharmacopeia. 34th ed. Rockville; 2011.Google Scholar
- 20.Thomas S, Agarwal A, Rao RD, Mathela CS. Characterization of an unknown impurity in citalopram hydrobromide active pharmaceutical ingredient by semi-preparative isolation and LC-ESI/MSn and NMR. J Liq Chromatogr Relat Technol. 2013;36:1999–2002.Google Scholar